查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1781927

非小細胞肺癌治療市場，按療法、按配銷通路、按癌症類型、按國家和地區 - 2025 年至 2032 年全球行業分析、市場規模、市場佔有率和預測

Non-Small Cell Lung Cancer Therapeutics Market, By Therapy, By Distribution Channel, By Cancer Type, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 288 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告重點

2024 年非小細胞肺癌治療市場規模價值 214.612 億美元，2025 年至 2032 年的複合年成長率為 12.99%。

非小細胞肺癌治療市場-市場動態

非小細胞肺癌治療市場的發展受到持續吸煙和日益嚴重的環境污染導致全球肺癌發病率上升的推動，這推動了對高效治療的需求。世界衛生組織稱，肺癌是全球主要癌症殺手之一。此外，非小細胞肺癌分子機制的快速發展為標靶治療和免疫療法的研發開闢了道路，這些療法有望實現更精準、毒性更低的治療。對新的生物標記和治療標靶的進一步研究有望創造更個人化的醫療模式。免疫療法與標靶藥物的結合取得了令人鼓舞的成果，能夠改善患者的預後，尤其是在晚期患者中。

此外，液體活體組織切片等先進診斷技術的應用日益廣泛，有助於識別和追蹤早期治療的反應，從而實現更早、更有效的治療。新興市場醫療基礎設施的完善以及高階癌症治療的普及也帶來了巨大的成長機會。然而，一些新療法，尤其是標靶療法和免疫療法，價格高昂，對全球相當一部分患者而言是一個巨大的進入門檻。複雜的監管環境和冗長的新產品核准流程也可能阻礙市場擴張。

非小細胞肺癌治療市場—關鍵見解

標靶治療擁有巨大的市場佔有率，因為它對治療特定分子亞型的非小細胞肺癌（NSCLC）非常有效，尤其是最常見的組織學亞型—腺癌。 EGFR、ALK 及其他標靶突變藥物的成功研發，使標靶治療成為 NSCLC 治療的主流，並提高了大多數存在這些突變的患者無惡化存活期。

預測期內，免疫療法正經歷最快的擴張。這可以歸因於其能夠在部分患者（即使是晚期患者）中產生持久的療效和長期生存獲益。免疫檢查點抑制劑的適應症日益增多，無論是單藥治療還是與化療或標靶治療聯合治療，均適用於各種亞型和分期的非小細胞肺癌 (NSCLC)，這推動了免疫療法的擴張。

預計線上藥局將成為成長最快的配銷通路。線上管道日益便利、可近性更高，有時更具成本效益，這推動了這一成長。遠距醫療和遠距照護服務的普及也促進了線上藥局在口服非小細胞肺癌藥物分銷方面的成長。

腺癌佔據了最大的市場佔有率，因為它是全球最常見的非小細胞肺癌組織學亞型，並且通常伴隨著某些基因突變，而這些突變可以透過現有的療法進行標靶治療。腺癌較高的發生率和可用的標靶療法使其成為治療市場的領導者。

非小細胞肺癌治療市場-細分分析：

全球非小細胞肺癌治療市場根據治療、配銷通路、癌症類型和地區進行細分。

依療法類型分類，市場可分為標靶治療、免疫療法和化療。標靶治療佔據了最大的市場佔有率。其主導地位源自於人們對非小細胞肺癌（NSCLC）分子背景的認知顯著提高，而辨識EGFR、ALK、ROS1和BRAF等致癌驅動基因已成為可能。針對這些突變的成功藥物的創新和獲批，改變了攜帶此類突變患者的治療模式，尤其是在腺癌患者中。標靶藥物在這些特定患者族群中通常比傳統化療療效更佳、毒性更小，因此成為初始治療和後續治療方案的關鍵要素。免疫治療是市場成長最快的領域。這種快速成長得益於免疫檢查點抑制劑的顛覆性效應，該抑制劑已被證明能夠在一定比例的多種NSCLC亞型患者中產生持續緩解和長期存活。將免疫療法的適應症拓展至疾病早期階段，並合併化療和標靶治療等其他療法，正在進一步推動市場成長。

根據配銷通路，市場細分為醫院藥房、零售藥房、線上藥房和其他。醫院藥房是最大的細分市場。由於非小細胞肺癌（NSCLC）的治療類型，該細分市場擁有最大的市場佔有率，這種治療通常包括複雜的靜脈注射療法，例如化療和大多數免疫療法。醫院擁有必要的基礎設施，例如專門的輸液中心和熟練的醫療保健專業人員，可以安全地提供和監控這些治療。此外，醫院藥局通常是住院期間處方藥和在專門的癌症中心接受治療的門診患者的初始配藥點。線上藥局是市場上成長最快的領域。電子商務的興起和線上網站日益便捷的購物體驗是其擴張的原因。線上藥局讓患者能夠輕鬆獲得用於治療非小細胞肺癌的口服藥物，包括標靶治療和某些支持性護理藥物。它們通常具有競爭力的價格和送貨上門的便利性，這對於患有肺癌等持續性疾病的患者尤其有幫助。

非小細胞肺癌治療市場—地理洞察

北美是非小細胞肺癌藥物最大的區域市場。這得益於多種因素，例如完善的醫療基礎設施、高昂的醫療支出以及大型製藥公司積極推動創新和早期採用新藥。美國是肺癌發病率最高的國家之一，但其高效的監管基礎設施使其能夠快速核准和採用新藥。此外，對研發的高度重視以及積極的報銷政策也鞏固了北美的領先地位。亞太地區是非小細胞肺癌藥物成長最快的地區。這種快速成長主要得益於中國和印度等市場龐大且不斷成長的患者群體、吸煙和空氣污染的日益嚴重以及醫療保健的可及性和可負擔性的不斷提高。醫療基礎設施支出的不斷成長以及免疫療法和標靶療法等先進癌症療法的使用率的不斷提高也是主要的成長動力。此外，臨床試驗數量的不斷增加和本地製藥行業的蓬勃發展也推動著該地區的快速成長。

非小細胞肺癌治療市場-競爭格局：

非小細胞肺癌治療市場競爭激烈，既有實力雄厚的製藥和生技公司，也有新進者。基因泰克（羅氏製藥）、禮來公司、阿斯特捷利康、輝瑞公司、百時美施貴寶和默沙東等主要公司憑藉其廣泛的獲批療法組合、雄厚的研發實力以及完善的全球分銷管道，佔據了巨大的市場佔有率。這些公司正在開發新的標靶療法、免疫療法和聯合療法，以滿足非小細胞肺癌患者不斷變化的需求並克服治療抗藥性。策略合作、授權協議和收購也加劇了競爭，旨在擴大產品線和市場覆蓋範圍。創新是差異化競爭的關鍵，各公司致力於發現新的治療標靶、開發下一代抑制劑以及抗體-藥物偶聯物和細胞療法等新型治療方法。人們對個人化醫療和基於生物標記的治療方法的日益關注也產生了競爭，各公司紛紛投資伴隨診斷來確定最有可能對其療法產生反應的患者亞群。

最新動態：

2024年12月：阿斯特捷利康和第一三共宣布，已向美國食品藥物管理局（FDA）提交了一份新的生物製劑許可申請（BLA），以加速批准達托泊單抗德魯替康（Dato-DXd）用於治療非小細胞肺癌（NSCLC）。此申請適用於先前接受過治療的不可切除或轉移性非鱗狀NSCLC成年患者。

2023年10月：禮來公司宣布FDA核准selpercatinib（Retevmo）用於治療經FDA核准的檢測方法檢測出RET融合陽性腫瘤的局部晚期或轉移性非小細胞肺癌成年患者。此項批准為該分子亞型的非小細胞肺癌（NSCLC）增加了治療選擇，提供了一種已證實有效的標靶治療方案。

2023年6月：百時美施貴寶公司宣布，美國食品藥物管理局（FDA）批准Opdivo（nivolumab）合併鉑類雙藥化療作為新輔助治療，隨後進行nivolumab單藥輔助治療，用於可切除（>=4 cm或淋巴結陽性）非小細胞肺癌成年患者。這為更晚期可切除患者在圍手術期提供了額外劑量的免疫療法治療。

2023年5月：安斯泰來與一家生技公司合作，研發針對多種癌症（包括非小細胞肺癌）的新型抗體藥物偶聯物。此次合作將結合安斯泰來在抗體工程方面的專業知識與合作夥伴專有的有效載荷技術，以開發更有效、更有針對性的肺癌治療方法。

目錄

第1章：非小細胞肺癌治療市場概述

  • 研究範圍
  • 市場估計年限

第2章：執行摘要

  • 市場片段
    • 非小細胞肺癌治療市場（按療法）
    • 非小細胞肺癌治療市場依配銷通路細分
    • 非小細胞肺癌治療市場依癌症類型分類
    • 非小細胞肺癌治療市場（按國家/地區）
    • 非小細胞肺癌治療市場（按地區）
  • 競爭洞察

第3章：非小細胞肺癌治療的主要市場趨勢

  • 非小細胞肺癌治療市場促進因素
    • 市場促進因素的影響分析
  • 非小細胞肺癌治療市場限制
    • 市場限制的影響分析
  • 非小細胞肺癌治療市場機遇
  • 非小細胞肺癌治療市場未來趨勢

第4章：非小細胞肺癌治療產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章：非小細胞肺癌治療市場：地緣政治緊張局勢升級的影響

  • COVID-19 疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：非小細胞肺癌治療市場格局

  • 2024年非小細胞肺癌治療市佔率分析
  • 按主要製造商分類的細分數據
    • 成熟玩家分析
    • 新興企業分析

第7章：非小細胞肺癌治療市場－按療法

  • 概述
    • 按療法細分的佔有率分析
    • 標靶治療
    • 免疫療法
    • 化療

第 8 章：非小細胞肺癌治療市場 - 按配銷通路

  • 概述
    • 按配銷通路分類的細分市場佔有率分析
    • 醫院藥房
    • 零售藥局
    • 網路藥局

第9章：非小細胞肺癌治療市場－依癌症類型

  • 概述
    • 按癌症類型分析細分佔有率
    • 腺癌
    • 鱗狀細胞癌
    • 大細胞癌

第 10 章：非小細胞肺癌治療市場 - 按地區

  • 介紹
    • 按地區分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美非小細胞肺癌治療主要製造商
    • 北美市場規模及預測（按國家/地區）
    • 北美市場規模及預測（按療法）
    • 北美市場規模及預測（按配銷通路）
    • 北美市場規模及預測（按癌症類型）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲非小細胞肺癌治療主要製造商
    • 歐洲市場規模及預測（按國家/地區）
    • 歐洲市場規模及預測（按療法）
    • 歐洲市場規模及預測（按配銷通路）
    • 歐洲市場規模及預測（按癌症類型）
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區非小細胞肺癌治療主要製造商
    • 亞太地區市場規模及預測（依國家）
    • 亞太地區市場規模及預測（依療法）
    • 亞太地區市場規模及預測（按配銷通路）
    • 亞太地區市場規模及預測（依癌症類型）
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲非小細胞肺癌治療主要製造商
    • 拉丁美洲市場規模及預測（按國家/地區）
    • 拉丁美洲市場規模及預測（按療法）
    • 拉丁美洲市場規模及預測（按配銷通路）
    • 拉丁美洲市場規模及預測（按癌症類型）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲（MEA）
    • 概述
    • 中東和非洲非小細胞肺癌治療主要製造商
    • MEA 市場規模及預測（依國家/地區）
    • MEA 市場規模及預測（依療法）
    • MEA 市場規模及預測（依配銷通路）
    • MEA 市場規模及預測（以癌症類型）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 其餘地區

第 11 章：非小細胞肺癌治療產業主要供應商分析

  • 競爭儀錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司簡介
    • Genentech, Inc. (F. Hoffmann-La Roche Ltd)
    • Eli Lilly and Company
    • Celgene Corporation
    • AstraZeneca
    • Pfizer Inc.
    • Sanofi
    • Novartis AG
    • Astellas
    • Bristol Myers Squibb
    • Boehringer Ingelheim Pharmaceuticals, Inc.
    • Millennium Pharmaceuticals, Inc. (Takeda)
    • Merck Sharp & Dohme Corp.

第 12 章：360 度分析師視角

第 13 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV5369

REPORT HIGHLIGHT

Non-Small Cell Lung Cancer Therapeutics Market size was valued at US$ 21,461.20 Million in 2024, expanding at a CAGR of 12.99% from 2025 to 2032.

Non-small cell lung cancer (NSCLC) therapeutics include a wide range of pharmacological and interventional interventions used in the treatment of lung cancers that do not qualify as small cell lung cancer. The therapeutic regimen for NSCLC has come a long way, going beyond the conventional use of chemotherapy to include targeted therapies that take advantage of specific tumour cell genetic mutations and immunotherapies that use the body's immunity against cancer. These therapies suppress cancer cell proliferation, trigger apoptosis (programmed cell death), and suppress metastasis. A therapeutic approach is selected based on factors such as the histological subtype of NSCLC, the stage of cancer at the time of diagnosis, the presence of specific biomarkers, and the patient's health status. The goal of therapy for NSCLC is to prolong survival, improve the quality of life, and palliate symptoms due to disease.

Non-Small Cell Lung Cancer Therapeutics Market- Market Dynamics

The market for non-small cell lung cancer therapeutics is driven by the propelling global incidence of lung cancer due to relentless smoking patterns and rising environmental pollution, which drives the need for efficient treatments. Lung cancer is a major cancer killer globally, according to the World Health Organization. Moreover, the rapid advances in unraveling the molecular underpinnings of NSCLC have opened the way for the rationale of creating targeted therapies and immunotherapies that promise more precise and potentially less toxic treatment. Further investigations into new biomarkers and targets for therapy have the promise to create more personalized medicine modalities. Combining immunotherapy with targeted agents yields encouraging results that enhance patient outcomes, especially in advanced disease.

In addition, the growing use of advanced diagnosis, such as liquid biopsies to identify and track response to early treatment, enables earlier and more effective treatments. The growth in healthcare infrastructure and the rising exposure to sophisticated cancer treatment in emerging markets also offer significant growth opportunities. However, the high price of several new therapies, especially targeted and immunotherapies, is a huge access barrier for a substantial share of the patient population worldwide. The complicated regulatory environment and the long, drawn-out approval process for new products can also hold back market expansion.

Non-Small Cell Lung Cancer Therapeutics Market- Key Insights

Targeted therapy has a substantial market share because it is highly effective in treating specific molecular subtypes of NSCLC, especially adenocarcinoma, the most common histologic subtype. Success with EGFR, ALK, and other actionable mutation-targeted drugs has made targeted therapy a mainstay of NSCLC therapy, resulting in enhanced progression-free survival in most patients with these alterations.

Immunotherapy is witnessing the most rapid expansion during the forecast period. This can be ascribed to its capability to yield durable responses and long-term survival benefits in a proportion of patients, even in advanced disease stages. Growing indications for immune checkpoint inhibitors, both in monotherapy and in combination with chemotherapy or targeted therapy, across various subtypes and stages of NSCLC are fueling this expansion.

Online pharmacies are projected to be the most rapidly growing distribution channel. The growth is fueled by increasing convenience, accessibility, and sometimes cost-effectiveness provided by online channels. Increased adoption of telemedicine and remote care services also enhances the growth of online pharmacies for oral NSCLC medication distribution.

Adenocarcinoma accounted for the largest market share as it is the world's most prevalent histological subtype of NSCLC and often presents with certain genetic mutations that are targetable with therapies presently available. Its larger prevalence and available targeted therapies have helped it become a leading player in the therapeutics market.

Non-Small Cell Lung Cancer Therapeutics Market- Segmentation Analysis:

The Global Non-Small Cell Lung Cancer Therapeutics Market is segmented on the basis of Therapy, Distribution Channel, Cancer Type, and Region.

By therapy, the market is segmented into targeted therapy, immunotherapy, and chemotherapy. Targeted therapy is the most significant share of the market. The dominance results from the vast improvement in realizing the molecular background of NSCLC, where identifying certain oncogenic drivers like EGFR, ALK, ROS1, and BRAF has become possible. The innovation and approval of successful drugs targeting these mutations have transformed the treatment model of patients carrying such changes, especially in adenocarcinoma. Targeted agents commonly demonstrate greater efficacy and better toxicity profiles than conventional chemotherapy in these particular patient groups and, hence, are a key element of initial and follow-up treatment protocols. Immunotherapy is the quickest-growing segment of the market. This fast growth is driven by the game-changing effect of immune checkpoint inhibitors, which have proven the capability to yield sustained responses and long-term survival in a proportion of patients with a range of NSCLC subtypes. Broadening immunotherapy indications to the earlier stages of the disease and combined with other modalities, such as chemotherapy and targeted therapy is further propelling market growth.

Based on Distribution Channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others. Hospital pharmacies are the biggest segment of the market. This segment has the greatest market share because of the type of treatment for NSCLC, which frequently includes the delivery of complicated intravenous therapy like chemotherapy and most immunotherapies. Hospitals have the required infrastructure, such as specialized infusion centers and skilled healthcare professionals, to deliver and monitor these treatments safely. In addition, hospital pharmacies are most often the initial dispensing point for drugs prescribed during an inpatient stay and for outpatients treated in specialized cancer centers. Online pharmacies are the most rapidly expanding sector in the market. The rise in take-up of e-commerce and the growing convenience provided by online websites are the reasons behind this expansion. Online drugstores give patients convenient access to oral drugs employed in treating NSCLC, including targeted treatments and certain supportive care medicines. They tend to have competitive prices and home delivery convenience, which can prove especially helpful for patients with ongoing conditions like lung cancer.

Non-Small Cell Lung Cancer Therapeutics Market- Geographical Insights

North America is the largest regional market for non-small cell lung cancer medicines. This is due to several factors, such as well-established healthcare infrastructure, high healthcare spending, and major pharmaceutical firms pushing innovation and early adoption of new medicines. The US has one of the highest rates of lung cancer and an effective regulatory infrastructure that allows for quick approval & adoption of new drugs. Furthermore, the strong focus on research and development, as well as positive reimbursement policies, adds to the leadership of North America. The Asia-Pacific region has the fastest growth for non-small cell lung cancer drugs. This rapid growth is largely the result of the huge and increasing patient base in markets such as China and India, the growing incidence of smoking and air pollution, and enhancing accessibility and affordability of healthcare. The ever-increasing rate of expenditure on healthcare infrastructure and the increasing rate of utilization of advanced cancer therapies such as immunotherapy & targeted therapy are also major growth drivers. Further, the rising number of clinical trials & development of local pharma industries are pushing the region's rapid growth.

Non-Small Cell Lung Cancer Therapeutics Market- Competitive Landscape:

The market for non-small cell lung cancer therapeutics is a highly competitive one with many entrenched pharma and biotech firms, as well as new entrants. Major players like Genentech (F. Hoffmann-La Roche Ltd), Eli Lilly and Company, AstraZeneca, Pfizer Inc., Bristol Myers Squibb, and Merck Sharp & Dohme Corp. command large market shares fueled by the broad portfolios of approved treatments, research and development strengths, and established global distribution channels. These companies are developing new targeted therapies, immunotherapies, and combination regimens to address the evolving needs of NSCLC patients and overcome resistance to treatments. Strategic collaborations, licensing agreements, and buyouts also increased the competitive intensity to expand product pipelines and market coverage. Innovation is an area of differentiator, where firms are targeting the identification of new targets of therapy, next-generation inhibitors, and novel treatment approaches such as antibody-drug conjugates and cell therapies. The rising focus on personalized medicine and biomarker-based treatment approaches also generates competition, with firms investing in companion diagnostics to determine patient subsets most likely to respond to their therapies.

Recent Developments:

December 2024: AstraZeneca and Daiichi Sankyo reported that they had submitted a new biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of datopotamab deruxtecan (Dato-DXd) as a therapy for non-small cell lung cancer (NSCLC). The application is in adult patients previously treated with unresectable or metastatic NSCLC non-squamous.

October 2023: Eli Lilly and Company announced FDA approval of selpercatinib (Retevmo) in adult patients with a rearranged during transfection4 (RET) fusion-positive tumor detected by an FDA-approved test in locally advanced or metastatic non-small cell lung cancer. This approval adds to the treatment options for this molecular subtype of NSCLC, providing a targeted therapy with proven effectiveness.

June 2023: Bristol Myers Squibb reported on the FDA approval of Opdivo (nivolumab) in combination with platinum-doublet chemotherapy as neoadjuvant therapy followed by adjuvant monotherapy for nivolumab alone in adult patients with resectable (>=4 cm or node-positive) non-small cell lung cancer. This allows an additional dose of immunotherapy-based therapy in the perioperative setting for patients with more advanced resectable disease.

May 2023: Astellas collaborated with a biotech firm to discover and develop new antibody-drug conjugates targeting multiple cancers, including NSCLC. The collaboration will combine Astellas' expertise in antibody engineering with the partner's proprietary payload technology to develop more effective and targeted treatments for lung cancer.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Genentech, Inc. (F. Hoffmann-La Roche Ltd)
  • Eli Lilly and Company
  • Celgene Corporation
  • AstraZeneca
  • Pfizer Inc.
  • Sanofi
  • Novartis AG
  • Astellas
  • Bristol Myers Squibb
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Millennium Pharmaceuticals, Inc. (Takeda)
  • Merck Sharp & Dohme Corp.

GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, BY THERAPY - MARKET ANALYSIS, 2019 - 2032

  • Targeted Therapy
  • Immunotherapy
  • Chemotherapy

GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL - MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE - MARKET ANALYSIS, 2019 - 2032

  • Adenocarcinoma
  • Squamous Cell Carcinoma
  • Large Cell Carcinoma

GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Non-Small Cell Lung Cancer Therapeutics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Non-Small Cell Lung Cancer Therapeutics Market Snippet By Therapy
    • 2.1.2. Non-Small Cell Lung Cancer Therapeutics Market Snippet By Distribution Channel
    • 2.1.3. Non-Small Cell Lung Cancer Therapeutics Market Snippet By Cancer Type
    • 2.1.4. Non-Small Cell Lung Cancer Therapeutics Market Snippet by Country
    • 2.1.5. Non-Small Cell Lung Cancer Therapeutics Market Snippet by Region
  • 2.2. Competitive Insights

3. Non-Small Cell Lung Cancer Therapeutics Key Market Trends

  • 3.1. Non-Small Cell Lung Cancer Therapeutics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Non-Small Cell Lung Cancer Therapeutics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Non-Small Cell Lung Cancer Therapeutics Market Opportunities
  • 3.4. Non-Small Cell Lung Cancer Therapeutics Market Future Trends

4. Non-Small Cell Lung Cancer Therapeutics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Non-Small Cell Lung Cancer Therapeutics Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Non-Small Cell Lung Cancer Therapeutics Market Landscape

  • 6.1. Non-Small Cell Lung Cancer Therapeutics Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Non-Small Cell Lung Cancer Therapeutics Market - By Therapy

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Therapy, 2024 & 2032 (%)
    • 7.1.2. Targeted Therapy
    • 7.1.3. Immunotherapy
    • 7.1.4. Chemotherapy

8. Non-Small Cell Lung Cancer Therapeutics Market - By Distribution Channel

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
    • 8.1.2. Hospital Pharmacies
    • 8.1.3. Retail Pharmacies
    • 8.1.4. Online Pharmacies

9. Non-Small Cell Lung Cancer Therapeutics Market - By Cancer Type

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Cancer Type, 2024 & 2032 (%)
    • 9.1.2. Adenocarcinoma
    • 9.1.3. Squamous Cell Carcinoma
    • 9.1.4. Large Cell Carcinoma

10. Non-Small Cell Lung Cancer Therapeutics Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Non-Small Cell Lung Cancer Therapeutics Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Non-Small Cell Lung Cancer Therapeutics Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.3.8. UK
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. UK Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.3.8.4. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.3.8.5. UK Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.3.9. France
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. France Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.3.9.4. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.3.9.5. France Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.3.10. Italy
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. Italy Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.3.10.4. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.3.10.5. Italy Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.3.11. Spain
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. Spain Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.3.11.5. Spain Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.3.12. The Netherlands
      • 10.3.12.1. Overview
      • 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.3. The Netherlands Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.3.12.4. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.3.12.5. The Netherlands Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Overview
      • 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.3.13.5. Sweden Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.3.14. Russia
      • 10.3.14.1. Overview
      • 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.3. Russia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.3.14.5. Russia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Poland Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Non-Small Cell Lung Cancer Therapeutics Key Manufacturers in Asia Pacific
    • 10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. APAC Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
    • 10.4.5. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.6. APAC Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.4.7. China
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. China Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.4.7.4. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.4.7.5. China Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.4.8. India
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. India Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.4.8.4. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.4.8.5. India Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.4.12. Indonesia
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Indonesia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Indonesia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.4.13. Thailand
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Thailand Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Thailand Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
  • 10.5. Latin America (LATAM)
    • 10.5.1. Overview
    • 10.5.2. Non-Small Cell Lung Cancer Therapeutics Key Manufacturers in Latin America
    • 10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. LATAM Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
    • 10.5.5. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.6. LATAM Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa (MEA)
    • 10.6.1. Overview
    • 10.6.2. Non-Small Cell Lung Cancer Therapeutics Key Manufacturers in Middle East and Africa
    • 10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. MEA Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
    • 10.6.5. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.6. MEA Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.6.8. UAE
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. UAE Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.6.8.4. UAE Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.6.8.5. UAE Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Non-Small Cell Lung Cancer Therapeutics Industry

  • 11.1. Competitive Dashboard
    • 11.1.1. Competitive Benchmarking
    • 11.1.2. Competitive Positioning
  • 11.2. Company Profiles
    • 11.2.1. Genentech, Inc. (F. Hoffmann-La Roche Ltd)
    • 11.2.2. Eli Lilly and Company
    • 11.2.3. Celgene Corporation
    • 11.2.4. AstraZeneca
    • 11.2.5. Pfizer Inc.
    • 11.2.6. Sanofi
    • 11.2.7. Novartis AG
    • 11.2.8. Astellas
    • 11.2.9. Bristol Myers Squibb
    • 11.2.10. Boehringer Ingelheim Pharmaceuticals, Inc.
    • 11.2.11. Millennium Pharmaceuticals, Inc. (Takeda)
    • 11.2.12. Merck Sharp & Dohme Corp.

12. 360 Degree AnalystView

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us